Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
VRK2
REST API REST API
Homo sapiens
VRK2 is differentially expressed in 258 experiments: 88 organism parts: prostate, cerebellum, ... (86 more);, 145 disease states: normal, acute lymphoblastic leukemia, ... (143 more);, 76 cell types 312 cell lines 38 compound treatments and 67 other conditions.
Orthologs vrk2 (Danio rerio)   YCK3 (Saccharomyces cerevisiae)   VRK2 (Gallus gallus)   YCK2 (Saccharomyces cerevisiae)   Vrk2 (Rattus norvegicus)   YCK1 (Saccharomyces cerevisiae)   VRK2 (Bos taurus)   ENSCING00000006395 (Ciona intestinalis)   Vrk2 (Mus musculus)   CG8878 (Drosophila melanogaster)   ball (Drosophila melanogaster)   vrk2 (Xenopus laevis)   VRK2 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term response to oxidative stress, endoplasmic reticulum, protein binding, cytoplasm, membrane, membrane fraction, regulation of MAPKKK cascade, ATP binding, transferase activity, transferring phosphorus-containing groups, nucleus, mitochondrial membrane, nucleotide binding, protein serine/threonine kinase activity, integral to membrane, endoplasmic reticulum membrane, protein kinase activity, protein autophosphorylation, protein phosphorylation, regulation of interleukin-1-mediated signaling pathway
InterPro Term Prot_kinase_cat_dom, Ser/Thr_kinase_dom, Ser-Thr/Tyr_kinase, Se/Thr_kinase-like_dom
UniProt Accession Q86Y07, B7Z2X1, E7ERS5, E9PBU1, E9PFA9
Search EB-eye ENSG00000028116
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-AFMX-5, E-MEXP-1251, E-MTAB-24, E-MTAB-25, ... (24 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-19639, E-GEOD-18005, E-GEOD-4717, ... (41 experiments)

Factor Value U/D Experiments
SW480
3
E-GEOD-18005, E-MEXP-1014, E-GEOD-2509
MCF-7
1
3
E-GEOD-19639, E-GEOD-20081, E-GEOD-3529, E-GEOD-5823
A549
1
2
E-GEOD-6013, E-GEOD-3202
MOLT4
2
E-MTAB-37, E-MTAB-62
U251
2
E-GEOD-20089, E-MTAB-62
K562
1
2
E-GEOD-24147, E-GEOD-96, E-MTAB-37
306 more value(s).


Cell type

studied in E-TABM-40, E-GEOD-22373, E-GEOD-21668, E-GEOD-3920, E-GEOD-4219, ... (38 experiments)

Factor Value U/D Experiments
macrophage
2
E-GEOD-22373, E-GEOD-5099
mesendoderm/endoderm progenitor cell
1
E-MEXP-930
ovarian cancer
1
E-GEOD-21154
adult choroid from 76 y.o. donor
1
E-GEOD-18811
CD326negCD56+ cell
1
E-GEOD-21668
adherent cell
1
E-MEXP-551
70 more value(s).


Disease state

studied in E-GEOD-3307, E-MEXP-1922, E-GEOD-6872, E-GEOD-1869, E-GEOD-5563, ... (46 experiments)

Factor Value U/D Experiments
acute lymphoblastic leukemia
3
E-MTAB-62, E-MTAB-37, E-GEOD-96
glioblastoma
3
E-MTAB-37, E-MTAB-62, E-GEOD-6014
lung adenocarcinoma
2
E-MTAB-62, E-MTAB-37
neuroblastoma
2
E-MTAB-37, E-MTAB-62
squamous cell carcinoma
2
E-MTAB-62, E-MTAB-37
muscle invasive carcinoma
1
E-GEOD-3167
139 more value(s).


Compound treatment

studied in E-GEOD-5258, E-GEOD-6907, E-GEOD-1432, E-GEOD-5824, E-TABM-868, ... (22 experiments)

Factor Value U/D Experiments
lipopolysaccharide
2
E-MEXP-1958, E-TABM-868
placebo
1
E-MEXP-1327
bis [(+)-tartrato] diantimonate (III) dipotassium trihydrate
1
E-GEOD-6907
glucose
1
E-MEXP-941
glutamine
1
E-MEXP-941
dimethyl sulfoxide
1
E-GEOD-6932
32 more value(s).


Age at diagnosis

studied in E-GEOD-3494

Factor Value U/D Experiments
64
1
1
E-GEOD-3494


Agent
studied in E-GEOD-19519

Biosource provider
studied in E-TABM-325, E-MTAB-37

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

cd3
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-22097, E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-TABM-125, ... (8 experiments)

Clinical info
studied in E-MTAB-37, E-GEOD-6710, E-GEOD-19348, E-MEXP-1251, E-GEOD-21589, ... (6 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-1614, E-MTAB-62

Disease staging
studied in E-GEOD-19743, E-GEOD-2509, E-TABM-147, E-GEOD-3013

Environmental stress
studied in E-GEOD-1643

Estrogen receptor status
studied in E-GEOD-6532

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-4025, E-MEXP-1482, E-GEOD-17385, E-GEOD-20847, E-MEXP-563 ... (5 experiments)

Genotype
studied in E-MEXP-1996, E-GEOD-22056, E-GEOD-3494, E-GEOD-22593, E-TABM-321, ... (7 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-MEXP-1220, E-GEOD-5681, E-GEOD-12773, E-TABM-127, ... (10 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276, E-GEOD-20194, E-GEOD-16716

immunoprecipitated protein
studied in E-GEOD-21918

Individual
studied in E-TABM-325, E-MTAB-197, E-MEXP-2069, E-GEOD-1926, E-MEXP-1648, ... (34 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-12108, E-GEOD-12254, E-GEOD-9723, E-MEXP-561, ... (8 experiments)

Karyotype
studied in E-GEOD-7214, E-GEOD-12662

Material type
studied in E-MEXP-455

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-TABM-84

Organism status
studied in E-GEOD-19188

Phenotype
studied in E-GEOD-26495, E-GEOD-19703, E-GEOD-22152, E-GEOD-21750, E-GEOD-1657, ... (7 experiments)

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-19445, E-GEOD-19246

Replicate
studied in E-GEOD-10896

RNAi
studied in E-MEXP-1509, E-GEOD-1676, E-MEXP-101, E-GEOD-3697, E-MEXP-1857, ... (6 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-7307

Stimulation
studied in E-GEOD-11886, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-MEXP-1996

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Test result
studied in E-GEOD-1926, E-TABM-276, E-GEOD-2748

Treatment
studied in E-GEOD-16837, E-MEXP-973, E-GEOD-19246, E-GEOD-13818, E-GEOD-19815 ... (5 experiments)

Tumor grading
studied in E-GEOD-4290, E-GEOD-1561

Vehicle
studied in E-GEOD-5258

weight of protein recovered
studied in E-GEOD-21918

Processing time: 0.29 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM